ImaginAb Announces new Clinical Trial at Hull University Teaching Hospitals NHS Trust to Investigate CD8 ImmunoPET in Patients with Renal Cancer and Malignant Melanoma
Los Angeles, California, USA, December 6th, 2022 – ImaginAb…
ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer
Study designed to investigate the efficacy and safety of ISA101b…
NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage
Experienced life sciences executive Dr Ruben Herrendorff…
Biocomposites adds Mexico to its list of countries where STIMULAN is approved as an antibiotic carrier for use in bone and soft tissue
STIMULAN® gives surgeons the freedom to choose and combine the…
STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study
23 November 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM),…
ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences
Los Angeles, California, USA, November 22nd, 2022 – ImaginAb…
Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
AMSTERDAM, THE NETHERLANDS, November 16, 2022 – Synaffix B.V.…
ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure Biotechnology
Los Angeles, California, USA, November 15, 2022 – ImaginAb…
Destiny Pharma plc – XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government’s NIAID
Brighton, United Kingdom, 15th November 2022 - Destiny Pharma…
Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON
PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
15…
Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer Therapies’ Clinical Development Program
Agreement enables use of CD8 ImmunoPETTM Imaging Technology…
Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases
Industry expert Ulrik Mouritzen M.D. appointed Chief Executive…
Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe
The companies enter into a license agreement for the European…
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Access to up to $400 million expected to provide cash runway…
Sequana Medical to present at Jefferies London Healthcare Conference
Ghent, Belgium – 8 November 2022 – Sequana Medical NV (Euronext…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
